Drug intelligence / Profile preview

MT101-5 (Mthera Pharma)

Development stage: Unknown
Lead developer: Mthera Pharma
Modality: Small Molecules
Administration: Oral

Overview

MT101-5 is a standardized botanical drug candidate developed by Mthera Pharma for the treatment of Parkinson's disease. It is an ethanolic extract composed of three traditional medicinal herbs: *Genkwae Flos*, *Clematidis Radix*, and *Gastrodiae Rhizoma*. The drug was developed using Mthera's proprietary Multi-Component Multi-Target (MCMT) technology platform. Its primary mechanism of action is the inhibition of α-synuclein aggregation, which prevents the formation of Lewy bodies, a pathological hallmark of Parkinson's disease. MT101-5 is administered orally as a tablet and is currently in Phase 2 clinical trials to evaluate its safety and efficacy in patients with early-stage Parkinson's disease.

Targets

NR4A2 (Nuclear receptor subfamily 4 group A member 2)

Beyond the preview

Go deeper on MT101-5 (Mthera Pharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT101-5 (Mthera Pharma).

Explore the full profile